Enfortumab Vedotin
ApprovedRecruiting 2 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metastatic Urothelial Carcinoma
Conditions
Metastatic Urothelial Carcinoma
Trial Timeline
Jun 21, 2025 → Dec 31, 2027
NCT ID
NCT06862219About Enfortumab Vedotin
Enfortumab Vedotin is a approved stage product being developed by Astellas Pharma for Metastatic Urothelial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06862219. Target conditions include Metastatic Urothelial Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Urothelial Carcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07139977 | Phase 2 | Recruiting |
| NCT07347314 | Phase 2 | Recruiting |
| NCT06862219 | Approved | Recruiting |
| NCT06891560 | Phase 2 | Recruiting |
| NCT06553885 | Phase 2 | Recruiting |
| NCT06394570 | Phase 1/2 | Recruiting |
| NCT06011954 | Pre-clinical | Recruiting |
| NCT05868265 | Phase 2 | Recruiting |
| NCT04754191 | Phase 2 | Active |
| NCT05014139 | Phase 1 | Terminated |
| NCT04995419 | Phase 2 | Completed |
| NCT03219333 | Phase 2 | Completed |
| NCT03070990 | Phase 1 | Completed |
| NCT02091999 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Urothelial Carcinoma